title: Psychological and psychiatric aspects of treatment of obesity and nonalcoholic fatty liver disease.
abstract: Chronic illnesses incur a tremendous cost to American lives in dollars and quality of life. Outcomes in these illnesses are often affected by psychological, behavioral, and pharmacologic issues related to mental illness and psychological symptoms. This article focuses on psychological and psychiatric issues related to the treatment of obesity and nonalcoholic fatty liver disease (NAFLD), including available weight-loss interventions, the complex relationship between psychiatric disorders and obesity, and special considerations regarding use of psychiatric drugs in patients with or at risk for NAFLD and obesity. Recommendations for collaborative care of individuals with comorbid NAFLD and psychological disorders/symptoms are discussed.
authors: Department of Psychiatry, Virginia Commonwealth University, Richmond, 23298-0268, USA. kstewart2@mcvh-vcu.edu
authors: Karen E
authors: KE
authors: Stewart
authors: James L
authors: JL
authors: Levenson
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000150:complications / Q000188:drug therapy; D002908:Chronic Disease; D015897:Comorbidity; D005234:Fatty Liver / Q000188:drug therapy / Q000523:psychology*; D001068:Feeding and Eating Disorders / Q000150:complications / Q000188:drug therapy; D006801:Humans; D065626:Non-alcoholic Fatty Liver Disease; D009765:Obesity / Q000188:drug therapy / Q000209:etiology / Q000523:psychology*; D011613:Psychotherapy; D011619:Psychotropic Drugs / Q000627:therapeutic use; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects / Q000502:physiology
chemical_list: D019440:Anti-Obesity Agents; D011619:Psychotropic Drugs